- Home
- VECO vs AKRO Comparison
VECO vs AKRO Comparison
Compare VECO & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VECO
- AKRO
- Stock Information
- Founded
- VECO 1945
- AKRO 2017
- Country
- VECO United States
- AKRO United States
- Employees
- VECO N/A
- AKRO N/A
- Industry
- VECO Industrial Machinery/Components
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- VECO Technology
- AKRO Health Care
- Exchange
- VECO Nasdaq
- AKRO Nasdaq
- Market Cap
- VECO 1.2B
- AKRO 3.9B
- IPO Year
- VECO 1994
- AKRO 2019
- Fundamental
- Price
- VECO $20.69
- AKRO $51.41
- Analyst Decision
- VECO Buy
- AKRO Strong Buy
- Analyst Count
- VECO 7
- AKRO 6
- Target Price
- VECO $30.43
- AKRO $82.50
- AVG Volume (30 Days)
- VECO 708.9K
- AKRO 1.8M
- Earning Date
- VECO 08-05-2025
- AKRO 08-08-2025
- Dividend Yield
- VECO N/A
- AKRO N/A
- EPS Growth
- VECO N/A
- AKRO N/A
- EPS
- VECO 1.07
- AKRO N/A
- Revenue
- VECO $710,109,000.00
- AKRO N/A
- Revenue This Year
- VECO N/A
- AKRO N/A
- Revenue Next Year
- VECO $10.08
- AKRO N/A
- P/E Ratio
- VECO $19.45
- AKRO N/A
- Revenue Growth
- VECO 3.30
- AKRO N/A
- 52 Week Low
- VECO $16.92
- AKRO $21.02
- 52 Week High
- VECO $49.25
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- VECO 52.17
- AKRO 47.91
- Support Level
- VECO $19.40
- AKRO $53.05
- Resistance Level
- VECO $21.67
- AKRO $57.35
- Average True Range (ATR)
- VECO 0.73
- AKRO 2.45
- MACD
- VECO -0.04
- AKRO -0.64
- Stochastic Oscillator
- VECO 47.78
- AKRO 4.65
About VECO Veeco Instruments Inc.
Veeco Instruments Inc is a United States-based company engaged in designing, developing, and manufacturing thin-film process equipment, mainly used for producing electronic devices. The company focuses on semiconductor process equipment that addresses a range of challenging materials engineering problems for our customers. Its products include Laser Processing Systems, Lithography Systems, Ion Beam Systems, SiC CVD Systems, MOCVD Systems, Wet Processing Systems, MBE Technologies, Atomic Layer Deposition Systems, Physical Vapor Deposition Systems, Dicing and Lapping Systems, as well as Gas & Vapor Delivery Systems. The majority of the company's revenue is generated from sales to the Semiconductor Industry and within China.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.